Benefits and harm of systemic steroids for short‐ and long‐term use in rhinitis and rhinosinusitis: an EAACI position paper. Issue 1 (3rd January 2020)

• Record Type: Journal Article
• Authors: Hox, Valerie; Lourijsen, Evelijn; Jordens, Arnout; Aasbjerg, Kristian; Agache, Ioana; Alobid, Isam; Bachert, Claus; Boussery, Koen; Campo, Paloma; Fokkens, Wytske; Hellings, Peter; Hopkins, Claire; Klimek, Ludger; Mäkelä, Mika; Mösges, Ralph; Mullol, Joaquim; Pujols, Laura; Rondon, Carmen; Rudenko, Michael; Toppila‐Salmi, Sanna; Scadding, Glenis; Scheire, Sophie; Tomazic, Peter‐Valentin; Van Zele, Thibaut; Wagenmann, Martin; van Boven, Job F. M.; Gevaert, Philippe
• Is Part Of: Clinical and translational allergy. Volume 10:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-01-03
• Subjects: Glucocorticosteroids -- Rhinitis -- Rhinosinusitis; Allergy -- Periodicals; Immunology -- Periodicals; Allergy and Immunology -- Periodicals; Hypersensitivity -- Periodicals; Immune System Phenomena -- Periodicals; 616.97005
• DOI: 10.1186/s13601-019-0303-6
• Languages: English
• ISSNs: 2045-7022

Abstract

Abstract: Because of the inflammatory mechanisms of most chronic upper airway diseases such as rhinitis and chronic rhinosinusitis, systemic steroids have been used for their treatment for decades. However, it has been very well documented that—potentially severe—side‐effects can occur with the accumulation of systemic steroid courses over the years. A consensus document summarizing the benefits of systemic steroids for each upper airway disease type, as well as highlighting the potential harms of this treatment is currently lacking. Therefore, a panel of international experts in the field of Rhinology reviewed the available literature with the aim of providing recommendations for the use of systemic steroids in treating upper airway disease.